UNASSIGNED: We retrospectively retrieved 72 consecutive cases of ASC diagnosed between February 2011 and March 2021. Both serum and tissue protein expression of YKL-40 were assessed, the latter in ASC tumor cells and peritumor immune cells.
UNASSIGNED: Increased YKL-40 serum levels at the time of diagnosis were associated with older age (p = 0.035), presence of cardiovascular/metabolic comorbidities (p = 0.007), and death for any cause (p = 0.011). In addition, high serum levels of YKL-40 were associated with a poor prognosis (HR: 2.82, 95% CI: 1.01-7.84; p = 0.047). Protein expression of YKL-40 in ASC tumor cells was significantly associated with low tumor grade (p = 0.031), while the increased expression in peritumor immune cells was associated with a worse response of patients to chemoradiotherapy (p = 0.007). However, YKL-40 protein expression in ASC tumor cells or peritumor immune cells did not significantly impact patient overall survival.
UNASSIGNED: In conclusion, YKL-40 resulted a relevant prognostic (serum level) and predictive (tissue protein expression in peritumor immune cells) biomarker and can considerably improve ASC patient clinical management.
■我们回顾性检索了2011年2月至2021年3月期间诊断的72例连续ASC病例。检测血清和组织中YKL-40蛋白的表达,后者在ASC肿瘤细胞和瘤周免疫细胞中。
■诊断时血清YKL-40水平升高与年龄增长有关(p=0.035),心血管/代谢合并症的存在(p=0.007),和任何原因的死亡(p=0.011)。此外,血清YKL-40水平升高与预后不良相关(HR:2.82,95%CI:1.01-7.84;p=0.047).YKL-40在ASC肿瘤细胞中的蛋白表达与低肿瘤分级显著相关(p=0.031),而肿瘤周围免疫细胞的表达增加与患者对放化疗的反应较差相关(p=0.007)。然而,ASC肿瘤细胞或肿瘤周围免疫细胞中的YKL-40蛋白表达对患者总生存期没有显著影响。
■总而言之,YKL-40产生相关的预后(血清水平)和预测性(肿瘤周围免疫细胞中的组织蛋白表达)生物标志物,并且可以显着改善ASC患者的临床管理。